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Introduction: Cardiovascular morbidity and mortality are increased in severe mental
illnesses (SMI). Trials of psychosocial health interventions to improve physical health in
SMI, including in treatment-resistant schizophrenia, have shown some benefit. However,
the representativeness of participants in such trials has not been determined.
Method: We utilized an anonymised case register to determine if participants in a
randomized controlled trial (RCT) of a novel psychosocial health intervention aiming to
improve physical health in SMI had similar severity of illness to eligible non-participants.
A retrospective database analysis was performed, using Health of the Nation Outcome
Scale (HoNOS) data from the sample of patients participating in the IMPaCT (Improving
Physical health and reducing substance use in Psychosis) RCT (n = 293) compared to
all eligible participants with a psychotic illness (n = 774).
Results: The mean total HoNOS score in the eligible comparator population
(Mean= 9.09, SD= 5.8, range= 0–30) was significantly greater than that of the IMPaCT
RCT participants (Mean= 7.16, SD= 4.7, range=0–26), (t = 3.810, p= 0.006), as was
the degree of overall illness severity and functional impairment, as measured by HoNOS.
Conclusion: This study shows for the first time that the patient population participating
in an RCT of a lifestyle intervention for those with SMI had a better mental health status
at entry to the trial, than the total eligible population, although there was no difference
in physical health needs. This has relevance to the applicability of RCTs of lifestyle
interventions in service planning and suggests that when people are more unwell, greater
effort may be needed to include them in psychosocial interventions. A more careful and
focused recruitment approach should be followed to improve the participation of the
more severely ill patients in psychosocial interventions in order to enhance the external
validity of such studies.
Keywords: schizophrenia, psychosis, outcomes, cardiovascular, health promotion intervention
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INTRODUCTION
People with severe mental illness (SMI), such as schizophrenia,
schizoaffective disorder and bipolar affective disorder, have
reduced life expectancy compared to those in the general
population (1–3). Most of this excess mortality is due to physical
illnesses, with cardiovascular disease prominent (4, 5). Meta-
analyses have demonstrated that targeted behavioral and non-
specific psychosocial interventions can be beneficial in reducing
antipsychotic induced weight gain and improving metabolic
parameters (6–8). However, in order to determine the external
validity of these findings (i.e., the extent to which the results can
be generalized to clinical practice), we must determine how the
extent to which participants in such studies are representative of
people with SMI.
Similar concerns have been raised in relation to inclusion
criteria for RCTs investigating the efficacy of clozapine in
treatment resistant schizophrenia (TRS), where a broader range
of patients are included than those meeting strict criteria for
treatment resistance, with inclusion of treatment intolerant and
non-refractory cases (9, 10).
Although there are examples of studies that have followed
up non-randomized patients in clinical trials making it possible
to assess and describe the generalizability of the results (11),
few studies involving people with SMI have compared the
characteristics of participating and non-participating patients,
thus limiting the external validity of study findings. One difficulty
in doing so lies in the ethical challenges of obtaining clinical
data pertaining to individuals who have not consented to
participate in the study (12, 13). The generalisability and real
world translation of research in SMI is further limited by non-
participation which may be selective (13). For example, at the
more severe spectrum of mental illness, people may lack the
capacity to consent to research, reducing the representativeness
of research samples (14). Participation rates for studies in SMI
are thought to be low, although this has not been as widely
documented as the high dropout rates in this population (15).
A recent survey of a large representative sample of people with
psychotic disorders identified that 65% (n = 773) of those
approached consented to participate in research, with older
people less likely to do so (16).
Obstacles to participation include illness severity (17–19),
fear of worsening of mental state due to participation (20),
and concerns about adverse treatment effects (21). Negative
symptomatology in patients with schizophrenia, with its inherent
poor motivation and communication difficulties, may further
reduce participation and limit the applicability of study findings
(13).
While there is extensive work aimed at improving the
participation of eligible patients (22) and identifying barriers
to patient participation in mental health research (23), little is
known about the clinical characteristics of non-participants. In
particular, no such data exists for studies of non-pharmacological
interventions to improve metabolic parameters in SMI, an
important gap in the evidence on which to plan services.
We set out to determine the clinical characteristics of patients
eligible to participate in the Improving Physical health and
reducing substance use in Psychosis (IMPaCT) randomized
controlled trial (RCT) (24) and compare these to the participating
group using the Health of the Nations Outcome Scale (HoNOS)
scores (25). We hypothesized that overall, individuals who were
eligible to participate in the RCT would be more severely ill
and functionally impaired as assessed by Health of the Nations
Outcome Scale (HoNOS) scores (25), compared to those who
agreed to participate.
MATERIALS AND METHODS
This current study is a secondary analysis of the Improving
Physical health and reducing substance use in Psychosis
(IMPaCT) cluster randomized controlled trial (RCT) (Trial
registration: ISRCTN58667926) (24, 26). The IMPaCT study is
a multicentre, two arm, parallel cluster randomized controlled
trial (RCT) of a psychosocial health promotion intervention
(IMPACT Therapy) in people with a diagnosis of SMI (24).
The patient-tailored IMPACT Therapy aimed to target one or
more health behaviors from a pre-defined list that includes
cannabis use; alcohol use; other substance use; cigarette
smoking; exercise; diet and diabetic control, prioritizing those
identified as problematic by the patient, taking a motivational
interviewing (MI) and cognitive behavioral therapy (CBT)
approach. Participants were permitted to start the community-
based IMPACT Therapy as soon as they were well-enough to
attend, even if they were in-patients, to mirror clinical practice
(24, 26).
The aim of this current study is to determine whether
participants in the IMPaCT RCTwere representative of the target
population in respect of levels of illness severity and functional
impairment.
Setting
The South London andMaudsley NHS Foundation Trust (SLaM)
is one of the largest providers of secondary mental health care
in Europe. It provides mental healthcare across four London
boroughs (Croydon, Lambeth, Lewisham, and Southwark) to a
population of 1.2 million. Since 2006, electronic records have
been used across all SLAM services. Since 2008 the Case Register
Interactive Search (CRIS) system has been developed to allow for
the search and retrieval of anonymised electronic clinical records
of patient data (27). Over 250,000 cases are currently represented
on CRIS in the form of detailed anonymised clinical information
(28). The protocol for this case register has been described in an
open-access publication (27).
Participants and Recruitment
In the IMPaCT RCT, to maximize inclusiveness, care
coordinators from continuing care/recovery teams, community
rehabilitation, assertive outreach, and community forensic teams
were recruited in random order and the eligible patients of
consenting care co-ordinators likewise approached for inclusion
in the study in random order. The inclusion criteria for IMPaCT
service user participants were as follows: male or female aged
between 18 and 65 years old; community patients with a primary
diagnosis of a non-affective psychotic disorder (ICD10 diagnostic
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criteria: F20.0–F29.0) or an affective psychotic disorder (F30–
33). Exclusion criteria included a primary diagnosis of learning
disability; a first episode of psychosis; serious physical illness
that could impact metabolic measures and substance misuse;
pregnant or up to 6 months post-partum; or receiving intensive
care for a medical or terminal condition.
In this present study, the comparator population comprised
the patients meeting the same inclusion criteria who were on the
overall caseload of each of the participating care coordinators.
The IMPaCT group were therefore a subset of the comparator
population.
Individuals on the comparator caseload were included
in the analysis if they had been assessed by a mental health
professional using the Health of the Nations Outcome
Scale (HoNOS) at least once in a time period of plus or
minus 6 months from the date of the recruitment of the
care coordinator to the IMPaCT RCT. If the individual had
required an acute psychiatric hospital admission during
that period they were excluded from the comparator
population. Further, if no HoNOS score was completed
in the 12 months study period, then the patient was
excluded.
Outcome Measures
The primary measure of interest was the total HoNOS scale
score, as this was routinely collected clinically and so was
available in the pseudoanonymised clinical sample as well as the
research sample. We compared HoNOS in patients participating
in the IMPaCT RCT compared to that of all patients with SMI
in the caseload of their care coordinators. Sociodemographic
characteristics were not taken for comparison, as this would have
potentially identified study non-participants.
The HoNOS has 12 items and four sections measuring,
respectively: behaviors, impairments, symptoms, and social
functioning (25).
A total score from the 12 items gives a measure of illness
severity. Individual items and subscales in the 4 domains
can be analyzed to assess their relative contributions to
global functioning. Each item is measured on a 5-point
Likert scale where; 0 = no problem within the period rated,
1 = sub-threshold problem, 2 = mild but definitely present,
3 = moderately severe, and 4 = severe to very severe, making
48 the highest possible score on the HoNOS (29).
Individuals in the total caseload who had a HoNOS score
assessed during the 12 months study period were included. In
the analysis we used the earliest HoNOS completed closest to
the recruitment date of the relevant care coordinator to the RCT.
HoNOS scores for individuals who had a hospitalization or an
admission to a high intensity community support team [such
as a Home Treatment Team (HTT)] within 6 months before or
after the recruitment date were excluded to reduce the likelihood
of us merely demonstrating that a short-term deterioration in
mental state reduces participation in community-based trials.We
did not exclude participants in the IMPaCT study group who
were admitted to hospital or to a Home Treatment Team (HTT)
following recruitment to the trial, although trial recruitment
solely took place in the community.
The HoNOS scores of interest for this analysis were total
HoNOS scale scores, subscale scores and individual itemized
HoNOS scale scores. Items 9, 10, 11, and 12 in particular were
assessed as a measure of functional impairment.
The means of total HoNOS scores from the overall care
coordinator caseload and IMPaCT RCT participants were
used as a proxy measure of global illness severity. Secondary
outcomes were the “functional impairment” HoNOS subscale,
which was composed of: item 9, “impairments in interpersonal
relationships” (such as social withdrawal); item 10- “impairments
in activities of daily living” (such as washing, dressing, mobility,
and use of transport); item 11- “deficits in the quality of
living conditions” (including absence of basic necessities such
as heat and light); and item 12- “impairments in occupational
functioning” (including the ability to engage in occupational and
recreational activities).
In the study, HoNOS ratings were conducted by mental health
professionals directly involved in the care of patients care for
the IMPaCT non-participants and by clinical researchers for
the IMPaCT study participants. It was not possible to measure
interrater reliability for HoNOS scores between the clinical staff
and the IMPaCT clinical researchers.
Statistical Analysis
For this analysis, a paired-samples t-test was used to compare:
1. total HoNOS scores from the overall caseload data set and
from the IMPaCT RCT participant data set
2. HoNOS subscale scores (items 9, 10, 11, and 12) in the overall
caseload data set and the IMPaCT RCT participant data set
3. individual HoNOS item scores between the overall caseload
group and the IMPaCT RCT participants group.
The statistical package SPSS version 24 was used for the analyses
and all t-tests were two-tailed with statistical significance set at an
alpha level of p ≤ 0.05.
RESULTS
The IMPaCT RCT recruited 293 eligible participants from within
SLaM, who were on the caseload of 68 care coordinators. In
this present study, using CRIS, we identified on the overall
caseload of each of the 68 eligible care coordinators, a total
comparator population comprising 1,109 patients who met the
inclusion criteria, including having a primary diagnosis of a
psychotic disorder. Of these 1,109 patients, 19 were excluded due
to incomplete HoNOS scoring in the 12 month period from the
time of the RCT recruitment, giving a HoNOS completion rate
of 98.3%, and leaving a total of 1,090 in the comparator group.
A further 316 (21.7% of those with a psychotic disorder) were
excluded having had a hospitalization or admission to a HTT
over the study period, leaving 774 patients in the comparator
group for analysis.
The mean total HoNOS score in the target population
(n = 774) (Mean = 9.09, SD = 5.8, range = 0–30) was
significantly greater than the mean total HoNOS score for the
IMPaCT RCT participating group (n = 293) (Mean = 7.16,
SD = 4.7, range =0–26), (t = 3.810, p < 0.001). Comparison
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TABLE 1 | Comparison of Mean HoNOS item scores between total caseload and RCT participants.
HoNOS scale item Mean HoNOS item scores for
Comparator group (n = 293)
Mean HoNOS item
scores for IMPaCT
group (n = 774)
Mean difference (SD)
between total caseload and
IMPaCT participants
T-test; p
Overactivity and aggression 0.49 0.33 0.16 (0.07) 2.284; 0.023*
Non-Accidental self-injury 0.10 0.09 0.01 (0.04) 0.262; 0.794
Problem drinking or drug-taking 0.32 0.33 −0.005 (0.07) −0.070; 0.945
Cognitive problems 0.74 0.53 0.215 (0.08) 2.855; 0.005*
Physical illness or disability problems 0.92 0.78 0.14 (0.01) −1.280; 0.201
Hallucinations and delusions 1.22 1.06 0.17 (0.11) −1.134; 0.258
Depressed mood 0.72 0.71 −0.10 (0.08) 1.469; 0.143
Other symptoms (not delusions or hallucinations) 1.25 0.95 0.29 (0.10) −2.787; 0.006*
Problems with relationships 1.08 0.78 0.30 (0.09) −3.388; 0.001*
Problems with Activities of daily living 1.07 0.74 0.34 (0.10) −3.041; 0.001*
Problems with living conditions 0.74 0.45 0.14 (0.08) 4.225; 0.003*
Problems with occupation and activities 0.75 0.60 0.16(0.10) −1.641; 0.102
Total HoNOS caseload-Total HoNOS IMPaCT 9.09 7.16 1.93 (0.51) 3.810; 0.001*
HoNOS functional impairment (items 9,10,11, and
12) caseload-HoNOS functional impairment IMPaCT
3.35 2.41 0.94 (0.24) 3.945; 0.001*
*p < 0.05.
of the individual HoNOS item scores between those participating
in the RCT and those on the care coordinators total caseload is
shown in Table 1.
There were significantly increased scores for HoNOS item
1 (overactive, aggressive, or agitated behavior regardless of
cause), item 4 (cognitive problems), item 8 (symptoms due to
other mental or behavioral problems), item 9 (problems with
relationships), item 10 (problems with activities of daily living),
and item 11 (problems with living conditions) in the comparator
group when compared to the IMPaCT participants (see Table 1).
There was no significant difference in the HoNOS scores on
the physical health item between the comparator group and the
IMPaCT study group [Mean difference (MD) =0.24; t = 1.408,
p= 0.161].
There was a significant increase in the HoNOS subgroup score
for items 9,10,11, and 12 in the comparator group [mean HoNOS
score for items 9,10,11, and 12 = 3.35 (SD = 2.6)] compared to
the IMPaCT group [mean HoNOS score for items 9,10,11, and
12 = 2.41 (SD = 2.3) (t = 3.945, p < 0.001]. This indicates that
the comparator group were more functionally impaired than the
IMPaCT study participants. The frequency of responses to each
of the HoNOS items by group is shown in Table 2.
DISCUSSION
To the best our knowledge, this is the first time that comparative
levels of illness severity and functional impairment in a large,
eligible non-participating group, and participating sample of a
psychosocial health intervention RCT in SMI have been explored.
This study demonstrates that both illness severity and functional
impairment were increased in the non-participating population
compared to the participating group. The overall health status
was better in the study population, and the less severely ill
patients were recruited to this trial.
Of interest, the levels of physical health problems were similar
between both groups. This is relevant, as the IMPaCT trial
intervention was designed to effect physical health improvements
in the study population. The comparability between physical
health impairment in both groups suggests that this did not
drive participation selection bias, as would have been indicated
by either increased severity of physical illness in the non-
participating comparator group or indeed, by people with more
physical health problems electing to participate. Instead, it
appears there was an equivalent physical health need, but that
other factors accounted for the difference in uptake of the
research opportunity.
Limitations of this study need to be considered. It was not
possible to assess for the effect of gender, age, ethnicity, and
duration of illness of the participating and non-participating
patient populations. Our inability to investigate factors that
may be predictive of non-trial participation is a limitation,
information that would be informative to improve the design
of future RCTs. Studies have indicated that older age (16,
23) and ethnicity (30), specifically black ethnicity (16), are
barriers to recruitment in mental health studies, factors which
may be related to illness severity. Clinical data that may have
impacted on study involvement, such as duration of illness
and number of psychiatric hospitalizations, were not available
in the pseudoanonymised comparator sample. However, the
two study populations were comparable on clinical symptoms
such as hallucinations/delusions, and depression, indicating that
active symptoms of mental illness were not impacting on the
participation rates between the groups. Data were obtained
retrospectively, which may limit the generalisability of the
findings. However, the recruitment of a patient population for
a prospective study would be difficult, and the method used
has enabled us to for the first time compare these groups in a
behavioral intervention in SMI.
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TABLE 2 | Cohort characteristics itemized by HoNOS scale items.
HoNOS items Total caseload
(n = 776)
N = (%)
IMPaCT participants
(n = 293)
N = (%)
OVERACTIVITY AND AGGRESSION
Not a problem 539 (70) 223 (76)
Subclinical, minor problems requiring
no action
153 (20) 53 (18)
Mild to very severe problem 84 (10) 23 (6)
NON-ACCIDENTAL SELF-INJURY
Not a problem 721 (93) 268 (91)
Subclinical, minor problems requiring
no action
46 (6) 26 (8.7)
Mild to very severe problem 9 (1) 1(0.3)
PROBLEM DRINKING OR DRUG-TAKING
Not a problem 585 (76) 223 (76)
Subclinical, minor problems requiring
no action
111 (14) 44 (15)
Mild to very severe problem 79 (10) 28 (9)
COGNITIVE PROBLEMS
Not a problem 416 (54) 166 (56)
Subclinical, minor problems requiring
no action
239 (31) 100 (34)
Mild to very severe problem 121 (15) 29 (10)
PHYSICAL ILLNESS OR DISABILITY PROBLEMS
Not a problem 357 (46) 155 (52)
Subclinical, minor problems requiring
no action
192 (25) 64 (22)
Mild to very severe problem 227 (29) 76 (26)
HALLUCINATIONS AND DELUSIONS
Not a problem 314 (41) 127 (43)
Subclinical, minor problems requiring
no action
171 (22) 47 (16)
Mild to very severe problem 290 (37) 121 (41)
DEPRESSED MOOD
Not a problem 394 (51) 147 (50)
Subclinical, minor problems requiring
no action
264 (34) 96 (33)
Mild to very severe problem 118 (15) 52 (17)
OTHER SYMPTOMS
Not a problem 94 (24) 124 (42)
Subclinical, minor problems requiring
no action
291 (38) 73 (25)
Mild to very severe problem 90 (38) 98 (33)
PROBLEMS WITH RELATIONSHIPS
Not a problem 79 (36) 136 (46)
Subclinical, minor problems requiring
no action
266 (35) 89 (30)
Mild to very severe problem 237 (29) 70 (24)
PROBLEMS WITH ACTIVITIES OF DAILY LIVING
Not a problem 338 (44) 161 (55)
Subclinical, minor problems requiring
no action
176 (23) 69 (23)
Mild to very severe problem 261 (33) 65 (22)
(Continued)
TABLE 2 | Continued
HoNOS items Total caseload
(n = 776)
N = (%)
IMPaCT participants
(n = 293)
N = (%)
PROBLEMS WITH LIVING CONDITIONS
Not a problem 545 (71) 221 (75)
Subclinical, minor problems requiring
no action
131 (17) 53 (18)
Mild to very severe problem 97 (12) 19 (7)
PROBLEMS WITH OCCUPATION AND ACTIVITIES
Not a problem 396 (51) 191 (65)
Subclinical, minor problems requiring
no action
193 (25) 55 (19)
Mild to very severe problem 183 (24) 48 (16)
In the analysis, we used only a single HoNOS score based
on the first HoNOS assessment in the relevant study period.
This precludes a more encompassing assessment of fluctuating
symptom profiles over time. The use of the HoNOS provides a
behavioral assessment of functioning at the level of individual
items, but does not allow for assessment of discrepancies between
behavior and inner experience. It may be that in a population of
individuals with SMI that the significantly increased functional
impairment in the inclusive comparator group is related to
negative symptomatology (31, 32), but this is something that we
were not able to assess.
In this study, HoNOS scores measured by care coordinators
for the comparator population were compared with those
measured by the IMPaCT RCT researchers. HoNOS is reported
to show a moderate inter-rater reliability, but this is improved
with training in HoNOS completion (33). Both care coordinators
and researchers in the IMPaCT RCT study were trained in the
use of the HoNOS, with the expectation that this would support
inter-rater reliability.
Strengths of this study include the size and comprehensiveness
of the sample. We were able to access the clinical records
of over 1,000 community dwelling individuals with psychotic
disorders. We looked at data specifically relating to individuals
with SMI living in the community and purposefully excluded
those who were hospitalized over the study period. This aids the
applicability of our study findings to ambulatory research and
enhances the generalisability of the study findings. Due to the
comprehensiveness of the search tool, we were able to identify a
patient population that reflects the characteristics of patients seen
in standard clinical practice thus further enhancing the validity of
our findings.
An additional important finding in this study was the
high rate of HoNOS completion in the sample of community
dwelling patients with SMI (98% completion rate). This finding
demonstrates the clinical utility of the HoNOS and a high level
of acceptability for its use in community mental health settings,
although this was likely enhanced in UK practice by HoNOS
measures being used for funding models. These findings are
however mirrored in other community samples, such as in
New Zealand where high completion rates of the HoNOS are
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documented, more so than in inpatient settings (95 and 79%
respectively) (34).
The greater illness severity in the comparator group as
compared to the participating group is unlikely to be a result of
the recruitment and randomizationmethod in the IMPaCT RCT.
An important recruitment factor in the IMPaCT RCTwas the use
of relatively wide inclusion criteria, including dual diagnosis, and
complex patients.
We cannot tell from these data whether the more ill patients
would have participated in the psychosocial health promotion
intervention were it not part of a clinical trial. If research itself
were the barrier, it raises questions as to whether published
research into psychosocial interventions for physical health
is applicable to the patients with the greatest impairment
in health and social functioning. This mirrors more broad
concerns regarding the representativeness of RCTs of treatment
interventions in SMI, and how this impacts on translation to real
world clinical practice. Observational data can help in this regard.
Clinical implementation trials for physical health problems in
SMI are required (35), which may be pragmatic large scale trials
to ensure broad inclusion criteria, heterogeneous populations
and assessment of the real world effectiveness of psychosocial
interventions for physical health (36). There remains limited
data on what factors predict entry to psychosocial intervention
trials in SMI. An increased awareness of this may aid increased
knowledge of when medication based and/or psychosocial
interventions are preferable to psychosocial interventions alone.
Our findings have implications for future RCTs of
psychosocial intervention in SMI. The study finding that
individuals with greater functional impairment are less likely
to participate in RCTs should lead to focused interventions
to increase their participation. This is required in order to
ensure that trial results can be confidently translated into clinical
practice.
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